Patents by Inventor John Klich

John Klich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240408213
    Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.
    Type: Application
    Filed: May 3, 2024
    Publication date: December 12, 2024
    Inventors: Eric A. Appel, Joseph L. Mann, John Klich, Catherine M. Kasse
  • Patent number: 12144862
    Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: November 19, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Eric A. Appel, Joseph L. Mann, John Klich, Catherine M. Kasse
  • Patent number: 12005119
    Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: June 11, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Eric A. Appel, Joseph L. Mann, John Klich, Catherine M. Kasse
  • Publication number: 20240180825
    Abstract: An injectable hydrogel network is provided distinguishing a non-covalently cross-linked hydrogel network with polymers functionalized with hydrophobic fatty pendant groups hydrophobically cross-linked with liposomal nanoparticles in which the liposomal nanoparticles are the cross-linkers. As the hydrogel is injectable, it is easily administered under the skin and does not require invasive surgical implantation. After injection the hydrogel rapidly self-heals to form a robust solid-like depot that can persist in the body over relevant timescales. The material does not cause a negative immune response like many other materials do. The hydrogel can gradually degrade over time in the body and therefore would not require surgical removal.
    Type: Application
    Filed: April 19, 2022
    Publication date: June 6, 2024
    Inventors: Santiago Correa, John Klich, Eric Andrew Appel
  • Publication number: 20230372488
    Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.
    Type: Application
    Filed: May 23, 2023
    Publication date: November 23, 2023
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Eric A. APPEL, Joseph L. Mann, John Klich, Catherine M. Kasse